2025
SJR Q3
JCR Q4 · 1,4
100 matched articles
SCIE
Journal detail
Chemotherapy
- Publisher
- S. Karger AG
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
0009315714219794
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,442
- Quartile Q3
- H-Index 64
- Cites/doc 1,1
- Docs (3y) 89
- Cites (3y) 124
Clarivate
Web of Science · JCR · 2025
- JCR Q Q4
- JIF 1,4
- 5Y JIF 1,7
- JCI 0,34
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Drug Discovery Q3
- Infectious Diseases Q3
- Medicine (miscellaneous) Q3
- Oncology Q3
- Pharmacology Q3
- Pharmacology (medical) Q3
Areas
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Oncology | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q4 | 0,442 | 1,4 | 1,7 | 0,34 | Q4 | 64 |
| 2024 | Q3 | Q3 | 0,51 | 1,7 | 2 | 0,38 | Q4 | 63 |
| 2023 | Q2 | Q3 | 0,663 | 2 | 2,1 | 0,53 | Q3 | 63 |
| 2022 | Q2 | Q2 | 0,627 | 3,3 | 2,2 | 0,54 | Q3 | 63 |
| 2021 | Q2 | Q3 | 0,742 | 3,5 | 2,4 | 0,56 | Q3 | 63 |
| 2020 | Q3 | Q3 | 0,539 | 2,5 | 2,1 | 0,46 | Q3 | 63 |
| 2019 | Q2 | Q4 | 0,488 | 1,6 | 1,5 | 0,49 | Q3 | 63 |
| 2018 | — | Q4 | — | 1,6 | 1,4 | 0,49 | Q3 | — |
| 2017 | Q2 | Q3 | 0,524 | 2 | 1,6 | 0,33 | Q4 | 63 |
| 2016 | Q2 | Q4 | 0,536 | 0,8 | 1,3 | — | — | 63 |
| 2015 | Q2 | Q4 | 0,635 | 1 | 1,4 | — | — | 63 |
| 2014 | Q2 | Q4 | 0,724 | 1,3 | 1,3 | — | — | 63 |
| 2013 | Q2 | Q3 | 0,767 | 1,6 | 1,5 | — | — | 63 |
| 2012 | Q2 | Q3 | 0,735 | 2,1 | 1,8 | — | — | 63 |
| 2011 | Q2 | Q3 | 0,694 | 1,8 | 1,8 | — | — | 63 |
| 2010 | Q2 | Q3 | 0,662 | 2,1 | 1,7 | — | — | 63 |
| 2009 | — | Q3 | — | 2 | 1,5 | — | — | — |
| 2008 | — | Q3 | — | 1,5 | 1,5 | — | — | — |
| 2007 | — | Q3 | — | 1,5 | 1,5 | — | — | — |
| 2006 | — | Q3 | — | 1,5 | — | — | — | — |
| 2005 | — | Q3 | — | 1,4 | — | — | — | — |
| 2004 | — | Q3 | — | 1,2 | — | — | — | — |
| 2003 | — | Q3 | — | 1,2 | — | — | — | — |
| 2002 | — | Q3 | — | 1 | — | — | — | — |
| 2001 | — | Q3 | — | 1,1 | — | — | — | — |
| 2000 | — | Q3 | — | 1 | — | — | — | — |
| 1999 | — | Q3 | — | 0,8 | — | — | — | — |
| 1998 | — | Q3 | — | 0,8 | — | — | — | — |
| 1997 | — | Q3 | — | 0,7 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q4 | Q4 | 287/333 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 295/356 |
| 2024 | ONCOLOGY | SCIE | Q4 | Q4 | 261/328 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q4 | 256/352 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q3 | 222/322 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 222/354 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q3 | 135/241 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 138/278 |
| 2021 | ONCOLOGY | SCIE | Q3 | Q3 | 156/245 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 144/279 |
| 2020 | ONCOLOGY | SCIE | Q4 | Q3 | 203/242 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 194/276 |
| 2019 | ONCOLOGY | SCIE | Q4 | Q3 | 223/244 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 226/271 |
| 2018 | ONCOLOGY | SCIE | Q4 | Q3 | 208/230 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 214/267 |
| 2017 | ONCOLOGY | SCIE | Q4 | Q4 | 176/223 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q4 | 173/261 |
| 2016 | ONCOLOGY | SCIE | Q4 | — | 210/217 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 231/257 |
| 2015 | ONCOLOGY | SCIE | Q4 | — | 197/213 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 225/255 |
| 2014 | ONCOLOGY | SCIE | Q4 | — | 182/211 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 193/255 |
| 2013 | ONCOLOGY | SCIE | Q4 | — | 161/203 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 171/256 |
| 2012 | ONCOLOGY | SCIE | Q3 | — | 124/197 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 147/261 |
| 2011 | ONCOLOGY | SCIE | Q3 | — | 132/196 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 153/261 |
| 2010 | ONCOLOGY | SCIE | Q3 | — | 112/185 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 138/252 |
| 2009 | ONCOLOGY | SCIE | Q3 | — | 105/166 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 137/237 |
| 2008 | ONCOLOGY | SCIE | Q4 | — | 116/143 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 153/219 |
| 2007 | ONCOLOGY | SCIE | Q4 | — | 102/132 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 137/205 |
| 2006 | ONCOLOGY | SCIE | Q4 | — | 101/127 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 126/199 |
| 2005 | ONCOLOGY | SCIE | Q4 | — | 97/123 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 124/193 |
| 2004 | ONCOLOGY | SCIE | Q4 | — | 96/123 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 125/187 |
| 2003 | ONCOLOGY | SCIE | Q4 | — | 94/120 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 124/185 |
| 2002 | ONCOLOGY | SCIE | Q4 | — | 93/114 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 131/188 |
| 2001 | ONCOLOGY | SCIE | Q4 | — | 83/107 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 113/186 |
| 2000 | ONCOLOGY | SCIE | Q3 | — | 76/103 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 115/181 |
| 1999 | ONCOLOGY | SCIE | Q4 | — | 82/105 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 119/175 |
| 1998 | ONCOLOGY | SCIE | Q3 | — | 75/104 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 117/178 |
| 1997 | ONCOLOGY | SCIE | Q3 | — | 72/102 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 115/157 |